Lung cancer is the leading cause of cancer death in China and worldwide. An increasing annual incidence and 5-year overall survival (OS) rate lower than 20%[1,2] has been verified in recent years in which LUAD accounts for 80% of primary pulmonary tumors [3]. The health hazard and huge economical burden derived from LUAD promote the need for novel and efficient treatment based on chemotherapy and targeted therapy [4,5].
Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma
Lung Cancer | Geplaatst op 28.08.2021 12:00